Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy

BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sápi, Johanna, Kovács, Levente, Drexler, Dániel András, Kocsis, Pál, Gajári, Dávid, Sápi, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635016/
https://www.ncbi.nlm.nih.gov/pubmed/26540189
http://dx.doi.org/10.1371/journal.pone.0142190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635016/
https://www.ncbi.nlm.nih.gov/pubmed/26540189
http://dx.doi.org/10.1371/journal.pone.0142190

Ejemplares similares